Literature DB >> 12475006

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.

E G Favalli1, L Sinigaglia, M Varenna, C Arnoldi.   

Abstract

After introduction of infliximab for the treatment of rheumatoid arthritis (RA), there have been many reports of patients developing asymptomatic higher rate of antinuclear antibodies and anti-dsDNA antibodies than in non-infliximab-treated patients. However, only five clinical drug-induced lupus (DIL) cases have been documented following treatment with infliximab, in RA and in Crohn's diseases. We report a case of a 69-year-old female with a 5 year history of RA, whowas successfully treated with low-dose methotrexate (MTX) and infliximab (initially 3 mg/kg and from the fourth infusion 5 mg/kg) for 23 weeks. Before the sixth infusion, she was diagnosed with DIL by both clinical features (fever > 38 degrees C, recurrence of active synovitis, myalgia, erythematous rash and general malaise) and laboratory findings (antinuclear antibodies 1:160, anti-double-stranded DNA positive by ELISA assay, decreased serum complement C3 andC4, hypergammaglobulinaemia, increased erythrocyte sedimentation rate). After discontinuation of treatment and therapy with oral prednisone, lupus resolved within 8 weeks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475006     DOI: 10.1191/0961203302lu236cr

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  13 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  A practical approach to screening psoriasis patients for therapy with biologic agents.

Authors: 
Journal:  J Clin Aesthet Dermatol       Date:  2008-09

3.  A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

Review 4.  TREG-cell therapies for autoimmune rheumatic diseases.

Authors:  Makoto Miyara; Yoshinaga Ito; Shimon Sakaguchi
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

5.  Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.

Authors:  Paola Caramaschi; Domenico Biasi; Elisabetta Tonolli; Sara Pieropan; Nicola Martinelli; Antonio Carletto; Alessandro Volpe; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2005-02-23       Impact factor: 2.631

6.  Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab.

Authors:  Daiju Iwata; Kenichi Namba; Kazuomi Mizuuchi; Nobuyoshi Kitaichi; Satoru Kase; Yuko Takemoto; Shigeaki Ohno; Susumu Ishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-11       Impact factor: 3.117

Review 7.  Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials.

Authors:  Amy C Cannella; James R O'Dell
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.

Authors:  Paola Caramaschi; Domenico Biasi; Marco Colombatti; Sara Pieropan; Nicola Martinelli; Antonio Carletto; Alessandro Volpe; Luisa Maria Pacor; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2004-12-31       Impact factor: 2.631

9.  Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.

Authors:  M Feletar; J E Brockbank; C T Schentag; V Lapp; D D Gladman
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

Review 10.  Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease.

Authors:  T D Myers; J R Smith; M S Wertheim; R A Egan; W T Shults; J T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.